Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

被引：1

作者：

Cottereau, Anne Segolene ^{[1
]}

Versari, Annibale ^{[2
]}

Loft, Annika ^{[3
]}

Casasnovas, Rene-Olivier ^{[4
]}

Bellei, Monica ^{[5
]}

Ricci, Romain ^{[6
]}

Bardet, Stephane ^{[7
]}

Castagnoli, Antonio ^{[8
]}

Brice, Pauline ^{[9
]}

Raemaeker, John ^{[10
]}

Itti, Emmanuel ^{[11
]}

Forpied, Catherine ^{[11
]}

Raveloarivahy, Tiana ^{[12
]}

Girinsky, Theodore ^{[13
]}

Van der Borght, Thierry ^{[14
]}

Federico, Massimo ^{[15
]}

Hutchings, Martin ^{[16
]}

Ricardi, Umberto ^{[17
]}

Meignan, Michel ^{[18
]}

Andre, Marc ^{[19
]}

机构：

[1] Hop Henri Mondor, Nucl Med, Creteil, France

[2] Santa Maria Nuova Hosp, Reggio Emilia, Italy

[3] Copenhagen Univ Hosp, Dep Clin Physiol, Nucl Med, Rigshosp, Copenhagen, Denmark

[4] Univ Hosp, Hematol, Dijon, France

[5] Univ Modena & Reggio Emilia, Dept Diagnost & Clin Med & Publ Hlth, Modena, Italy

[6] LYSARC LYSA Hop Henri Mondor, Creteil, France

[7] CLCC Francois Baclesse, Dept Nucl Med, Caen, France

[8] Osped Santo Stefano, Nucl Med Unit, Prato, Italy

[9] Hop St Louis, APHP, Hematol, Paris, France

[10] Radboud Univ Nijmegen, Med Ctr, Hematol, Nijmegen, Netherlands

[11] Grp Hosp Mondor, APHP, Dept Nucl Med, Creteil, France

[12] European Org Res Treatment Canc, Brussels, Belgium

[13] Inst Gustave Roussy, Villejuif, France

[14] Catholic Univ Louvain, Div Nucl Med, Louvain, Belgium

[15] Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, Modena, Italy

[16] Rigshosp, Dept Hematol, Copenhagen, Denmark

[17] AO Citta Salute Sci, Sez Radioterapia, Dipartimento Oncol, Turin, Italy

[18] Henri Mondor Univ Hosp, Dept Nucl Med, Creteil, France

[19] CHU UCL NAMUR, Dept Hematol, Yvoir, Belgium

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.184.184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

184

引用

页数：5

共 36 条

[31] Quality of life in early stage Hodgkin lymphoma (HL) patients from the EORTC-GELA H8 Trial (20931): A post-treatment longitudinal study of 1,015 patients
Mounier, N.
Heutte, N.
Flechtner, H.
Mellink, A. M.
Brice, P.
Gaillard, I.
Traulle, C.
Ferme, C.
Eghbali, H.
Henry-Amar, M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[32] AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.
Casasnovas, Rene-Olivier
Meignan, Michel
Reman, Oumedaly
Gaillard, Isabelle
Stamatoullas, Aspasia
Brice, Pauline
Salles, Gilles A.
Bouabdallah, Reda
Bologna, Serge
Nicolas-Virelizier, Emmanuelle
Morschhauser, Franck
Janvier, Maud
Andre, Marc
Berriolo-Riedinger, Alina
Traverse-Glehen, Alexandra
Edeline, Veronique
Dartigues, Peggy
Parrens, Marie
Mounier, Nicolas
Ferme, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial
Heutte, Natacha
Flechtner, Henning H.
Mounier, Nicolas
Mellink, Wilhelmina A. M.
Meerwaldt, Jacobus H.
Eghbali, Houchingue
van't Veer, Mars B.
Noordijk, Evert M.
Kluin-Nelemans, Johanna C.
Lampka, Elzbieta
Thomas, Jose
Lugtenburg, Pieternella J.
Viterbo, Luisa
Carde, Patrice
Hagenbeek, Anton
van der Maazen, Richard W. M.
Smit, Wilma G. J. M.
Brice, Pauline
Kooy, Marinus van Marwijk
Baars, Johanna W.
Poortmans, Philip
Tirelli, Umberto
Leeksma, Onno C.
Tomsic, Radka
Feugier, Pierre
Salles, Gilles
Gabarre, Jean
Kersten, Marie Jose
Van Den Neste, Eric
Creemers, Geert-Jan M.
Gaillard, Isabelle
Meijnders, Paul
Tertian, Gerard
Reman, Oumedaly
Muller, Hein P.
Troncy, Jacques
Blanc, Michel
Schroyens, Wilfried
Voogt, Paul J.
Wijermans, Pierre
Rieux, Chantal
Ferme, Christophe
Henry-Amar, Michel
LANCET ONCOLOGY, 2009, 10 (12): : 1160 - 1170
[34] Results of the EORTC-GELA H9 randomized trials:: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)
Thomas, J.
Ferme, C.
Noordijk, E. M.
van't Veer, M. B.
Brice, P.
Divine, M.
Morschhauser, F.
Carde, P.
Eghbali, H.
Henry-Amar, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 27 - 27
[35] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10
Mueller, R. P.
Eich, H. T.
Pluetschow, A.
Debus, J.
Bamberg, M.
Wilbom, K.
Eble, M.
Mueller-Hennelink, H.
Diehl, V.
Engert, A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S26 - S27
[36] First results of the EORTC-GELA H9 randomized trials:: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL).
Noordijk, EM
Thomas, J
Fermé, C
Van 't Veer, MB
Brice, P
Diviné, M
Morschhauser, F
Carde, P
Eghbali, H
Henry-Amar, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 561S - 561S

← 1 2 3 4 →